Emerging Therapeutic Targets and Drug Delivery Approaches in IBD

1st Edition, Volume 101 - November 12, 2024
Editor: Florin Selaru
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 3 1 3 5 8 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 3 1 3 5 9 - 2

Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapte… Read more

Purchase options

Institutional subscription on ScienceDirect

Request a sales quote

Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapters on timely topics, including Fibrosis in IBD – AXL as a Promising Therapeutic Target, Developing a pathway to test anti-fibrotic drugs in Crohn’s disease, Emerging therapeutics for the management of intestinal fibrosis and strictures, GCPII for IBD, Fistulas/stem cell products for IBD/Crohn’s, The landscape of new therapeutic opportunities for IBD, TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis, Dectin-1 as a therapeutic target for IBD, and more.

Additional sections cover BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases, Scripps - S1P, The potential of targeting TREM-1 in Inflammatory Bowel Disease, and Microbiome therapies.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
References
Chapter One: The landscape of new therapeutic opportunities for IBD
Abstract
Graphical Abstract
1 Introduction: unmet therapeutic needs in IBD
2 Restoration of immune homeostasis
3 Restoration of barrier function and promotion of mucosal healing for prevention of disease progression
4 Reversing and preventing disease complications
5 Restoration of microbial homeostasis for disease management
6 Targeted drug delivery systems for enhanced therapeutic efficacy with minimal side effects
7 Precision medicine for personalized interventions
8 Path forward toward personalized and holistic care
Conflict of interest statement
References
Chapter Two: Anti-fibrotics in inflammatory bowel diseases: Challenges and successes
Abstract
Abbreviations
1 Introduction
2 Fibroblasts are the major contributor to the production of extracellular matrix in Crohn’s disease strictures
3 Smooth muscle hyperplasia in stricturing Crohn’s disease
4 Development of anti-fibrotic therapies in IBD
5 Clinical trials in stricturing Crohn’s disease
6 Conclusions
References
Chapter Three: Emerging therapeutics for the management of intestinal fibrosis and strictures
Abstract
Abbreviations
1 Introduction
2 Small molecule therapeutics
3 Biologics
4 Novel drug delivery systems
5 Conclusion
References
Chapter Four: AXL: A novel therapeutic target in IBD
Abstract
1 Introduction
2 Fibrosis is a complication of IBD
3 AXL molecular structure and function
4 AXL as a therapeutic target
5 AXL inhibition in colitis
6 AXL inhibition in colitis-associated carcinoma
7 AXL inhibition in fibrosis
8 Discussion/future directions
References
Chapter Five: Current and emerging therapeutic strategies for perianal fistula in Crohn’s disease patients
Abstract
1 Drugs and biologics
2 Surgery flaps and prosthetic plugs
3 Surgical glues
4 Hydrogel fillers
5 Regenerative treatments using MSCs
6 Regenerative treatments using extracellular vesicles (EVs)
7 Conclusion
References
Chapter Six: The discovery and development of the sphingosine 1-phosphate receptor modulator ozanimod in ulcerative colitis
Abstract
1 Introduction
2 Sphingosine-1 phosphate in physiology
3 Receptors for S1P
4 Solving therapeutic hurdles to invent ozanimod
5 Animal model evidence for ozanimod in inflammatory lesions of the bowel
6 Clinical efficacy in autoimmune disease
7 Clinical evidence for ozanimod in ulcerative colitis
8 Are there mechanistic clues that might be discernible for subsetting patient responses to S1P receptor agonists: (lessons from virology)
9 Conclusions
Acknowledgements
References
Chapter Seven: BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Abstract
Abbreviations
1 Introduction
2 Structure and function of BRD4
3 Drug discovery targeting BRD4 as a novel promising therapeutic strategy for IBD
4 Conclusions
5 Opportunities, challenges, and future directions
References
Chapter Eight: Dectin-1 as a therapeutic target for inflammatory bowel disease
Abstract
1 Introduction
2 Relationship between enteric fungi and IBD
3 The role of Dectin-1 in the interplay between fungal microbiota and IBD
4 Therapeutic potential of Dectin-1 in IBD
5 Future directions in research and therapy
References
Chapter Nine: Targeting glutamate carboxypeptidase II in IBD
Abstract
1 Introduction
2 Glutamate carboxypeptidase II (GCPII) biology
3 GCPII as a therapeutic target in IBD
4 GCPII inhibitor efficacy in preclinical colitis models
5 Development of first-in-class gut-restricted oral GCPII inhibitors
6 Concluding remarks
References
Chapter Ten: TL1A: A model for a precision medicine approach in the treatment of Crohn’s disease and ulcerative colitis
Abstract
References
Chapter Eleven: The potential of targeting TREM-1 in IBD
Abstract
1 Introduction
2 TREM-1 is a universal amplifier of the innate immune response
3 Soluble TREM-1
4 Innate immunity in the pathophysiology of IBD
5 The potential of targeting TREM-1 in IBD
6 TREM-1 ligands in IBD pathogenesis
7 Preclinical rational of targeting TREM-1 versus other pathways
8 Conclusions
Conflict of interest statement
References

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Emerging Therapeutic Targets and Drug Delivery Approaches in IBD

Purchase options

Institutional subscription on ScienceDirect